Eli Lilly to Launch Higher-Dose Weight-Loss Drug Zepbound at $499 Per Month
On June 16, 2025, Eli Lilly announced it will begin selling higher-dose versions of its popular weight-loss drug Zepbound through its website LillyDirect. Starting July 7, healthcare providers can prescribe the 12.5 mg and 15 mg vials, with shipments to self-paying patients beginning in early August.
The higher doses will cost $499 per month. Lilly had previously introduced the two lowest doses of Zepbound in vials last year and began offering them at a discount in February. Zepbound, typically sold in auto-injector pens, has gained significant popularity in the weight-loss market.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
2026-07-12
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Reducing to Refocus: Novo Nordisk’s 9,000-Job Cut and the Strategic Realignment in Pharma
-
Eli Lilly Strikes $1.3 Billion AI Deal with Superluminal for Next-Gen Obesity Drugs Targets GPCR Breakthrough
-
Eli Lilly to Raise UK Mounjaro Price 170 Percent Monthly Cost Jumps from £122 to £330
-
FDA Approves Precigen’s Papzimeos Immunotherapy 51 Percent of RRP Patients Avoid Surgery for One Year
-
IPEC Updates Excipient Qualification Guidance
-
Pharmaceutical Tariffs Put Ingredients Back in Focus
-
Novo Nordisk Launches Wegovy in South Africa One in Two Adults Faces Obesity as GLP-1 Drug Competition Heats Up
-
U.S. Onshoring Debate Exposes API Raw-Material Gap
-
BASF Raises API and Excipient Prices
-
Platinum Chemotherapy Shortages Expose the Fragility of Essential API Supply
Recommend Reading
-
The Oral GLP-1 Cage Match: Orforglipron vs Rybelsus
-
Sun Pharma’s Secret Sauce: Solve the Specific, Win the Market
-
FDA Orders Removal of “Suicidality Warning”: Are Weight-Loss Blockbusters Finally Cleared—or Is Regulators Giving the Market a Reality Check?
-
Pharma’s Tightrope in 2026: Safety, Competition and the Future of Obesity Treatment Innovation
-
Novo Nordisk Sounds the Alarm: Growth Headwinds Loom Over Global Operations in 2026
-
This Round of Refined Oil Retail Price Adjustment Faces Another Suspension
-
In mid-September, the price of 180CST fuel oil in China saw a slight increase
-
This week, the coke market in China was mainly weak.
-
Dow × Hisense’s Innovation Code: A Deep Game of Sustainability
-
Bullish and Bearish Forces Combine as Palm Oil Prices Fluctuate and Decline